查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1574965

朊病毒疾病治疗市场，按类型、治疗、最终用户、国家和地区 - 2024-2032 年行业分析、市场规模、市场份额和预测

Prion Disease Treatment Market, By Type, By Treatment, By End User, By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2024-2032
出版日期: | 出版商: AnalystView Market Insights | 英文 303 Pages | 商品交期: 2-3个工作天内

价格
简介目录

报告要点

2023年朊病毒疾病治疗市场规模为49.8498亿美元，2024年至2032年复合年增长率为4.99%。

朊病毒疾病治疗市场-市场动态

人们对针对特定朊病毒株的个人化医疗的兴趣日益浓厚，推动了利基市场的成长。

人们对针对特定朊病毒株的个人化医疗日益增长的兴趣是市场扩张的关键驱动力。这种方法根据不同人群菌株的独特特征来客製化诊断和治疗，提高介入措施的有效性。美国国家神经疾病和中风研究所 (NINDS) 的最新资料表明，个人化医疗策略可以将朊病毒疾病的诊断准确性提高高达 30%。这些进步凸显了更精确、更有效的治疗方案的潜力，直接影响市场动态。

随着医疗保健行业越来越多地采用个人化方法，对专业诊断工具和客製化疗法的需求不断增长。这种需求促进了帕金森氏症管理利基市场的创新和成长，强调了个人化医疗在解决复杂的神经退化性疾病方面的变革潜力。

朊病毒疾病治疗市场 - 关键见解

根据我们的研究分析师分享的分析，预计全球市场在预测期内（2024-2032 年）每年将以 4.99% 左右的复合年增长率成长

根据类型细分，克雅氏症 (CJD) 预计将在 2023 年显示最大的市场份额

根据治疗细分，抗忧郁药物是 2023 年的主要药物类型

按地区划分，北美是 2023 年的主要收入来源

朊病毒疾病治疗市场-細項分析：

全球朊病毒病治疗市场根据类型、治疗、最终用户和地区进行细分。

市场依类型分为四类：克雅氏症（CJD）、变异型克雅氏症（CJD）、可变蛋白酶敏感性朊病毒病、格斯特曼-施特劳斯勒-沙因克病、其他。在朊病毒病治疗市场中，克雅氏症（CJD）是最突出且最重要的部分。克雅氏症是人类最常见的朊病毒疾病，与其他朊病毒疾病相比，它的盛行率较高，因此成为人们关注的焦点。克雅氏症有多种形式，包括散发性、遗传性和后天性。散髮型是最常见的，发生时没有任何已知原因。由于研究兴趣高且疾病性质严重，克雅氏症的治疗前景特别活跃。开发克雅氏症有效疗法或疗法的努力往往会推动市场发展，使其成为主导细分市场。

根据治疗方法，市场分为两类：抗忧郁药、抗精神病药和其他药物。在朊病毒疾病治疗市场中，与抗精神病药物相比，抗忧郁药物更为突出且重要。抗忧郁药物通常用于治疗朊病毒病，特别是用于缓解忧郁、焦虑和躁动等症状，这些症状在克雅氏症 (CJD) 等朊病毒病患者中很常见。儘管朊病毒病无法治愈，但抗忧郁药物可以透过控制继发症状来帮助改善生活品质。朊病毒疾病的研究和治疗策略中对抗忧郁药物的关注使得这一细分市场更加重要并在市场上占据主导地位。

朊病毒疾病治疗市场-地理洞察

在北美，朊病毒病治疗是一个正在进行的研究领域，但临床选择有限。朊病毒疾病，例如克雅氏症 (CJD)，非常罕见，其特征是进行性神经退化。治疗策略着重于症状管理和实验疗法。人们非常重视开发有效药物的研究，多项临床试验探索新的化合物和方法，例如基因疗法和免疫疗法。

儘管朊病毒疾病的复杂性带来了挑战，但北美监管环境透过资金和监管途径支持这些努力。研究机构、医疗保健提供者和製药公司之间的合作对于推进治疗方案和改善患者治疗效果至关重要。

朊病毒疾病治疗市场-竞争格局：

朊病毒疾病治疗的竞争格局包括各种生物技术和製药公司应对这些疾病的独特挑战。 CureVac AG 正在探索 mRNA 技术的潜在治疗方法，而 Prionics AG 则专注于朊病毒疾病诊断。 Neurotech Pharmaceuticals 和 Prothena Biosciences 正在开发可能与朊病毒疾病相关的神经退化性疾病的疗法。 Alnylam Pharmaceuticals 和 IONIS Pharmaceuticals 致力于研究可能影响朊病毒病治疗的 RNA 疗法。百健（Biogen）、礼来公司（Eli Lilly and Company）和安进公司（Amgen Inc.）等主要参与者投资于更广泛的神经退化研究，以及潜在的朊病毒疾病治疗方法。基因泰克（罗氏集团）专注于创新的神经疗法。 Wave Life Sciences 和 Orphazyme A/S 分别正在探索 RNA 标靶疗法和罕见疾病疗法。 Sage Therapeutics 致力于治疗神经退化性疾病，而 Alector Inc. 则开发免疫疗法。 Tetra Discovery Partners 也正在研究可能与朊病毒疾病相关的神经系统疾病的治疗方法。这个多元化的公司集团凸显了旨在解决朊病毒疾病的复杂性的持续努力和创新。

最新进展：

2024 年 6 月，CHARMED 合作推出了一种有前景的朊病毒疾病治疗候选药物，可能为这些目前无法治疗的致命疾病带来新的希望。

2023年8月，Elite Pharmaceuticals Inc.宣布EP-1已被FDA授予治疗克雅氏症的快速通道资格。该程序被称为“快速通道指定”，旨在加速和简化旨在治疗严重或危及生命的疾病的药物的开发。

目录

第一章：朊病毒疾病治疗市场概述

  • 研究范围
  • 市场预估年份

第 2 章：执行摘要

  • 市场片段
    • 按类型分類的朊病毒疾病治疗市场片段
    • 朊病毒疾病治疗市场片段（依治疗）
    • 最终使用者的朊病毒疾病治疗市场片段
    • 按国家/地区分類的朊病毒疾病治疗市场片段
    • 按地区分類的朊病毒疾病治疗市场片段
  • 竞争洞察

第 3 章：朊病毒病治疗主要市场趋势

  • 朊病毒疾病治疗市场驱动因素
    • 市场驱动因素的影响分析
  • 朊病毒疾病治疗市场限制
    • 市场限制影响分析
  • 朊病毒疾病治疗市场机会
  • 朊病毒疾病治疗市场未来趋势

第 4 章：朊病毒疾病治疗产业研究

  • PEST分析
  • 波特五力分析
  • 成长前景图
  • 规范架构分析

第 5 章：朊病毒疾病治疗市场：COVID-19 影响分析

  • COVID-19 之前的影响分析
  • COVID-19 后影响分析
    • 表现最佳的市场区隔
    • 边际增长部分
    • 最鬆散的部分
    • 边际损失部分

第 6 章：朊病毒疾病治疗市场格局

  • 2023 年朊病毒疾病治疗市占率分析
  • 按主要製造商分類的故障数据
    • 既定玩家分析
    • 新兴玩家分析

第 7 章：朊病毒疾病治疗市场 - 按类型

  • 概述
    • 按类型分類的细分市场占有率分析
    • 克雅氏症 (CJD)
    • 变异型克雅氏症 (CJD)
    • 不同蛋白酶敏感性朊病毒病
    • 格斯特曼-施特劳斯勒-沙因克病
    • 其他的

第 8 章：朊病毒疾病治疗市场 - 按治疗分类

  • 概述
    • 按处理方式分類的细分市场占有率分析
    • 抗忧郁药
    • 抗精神病药
    • 其他的

第 9 章：朊病毒疾病治疗市场 - 按最终用户

  • 概述
    • 按最终用户分類的细分市场占有率分析
    • 医院
    • 家庭护理设置
    • 其他的

第 10 章：朊病毒疾病治疗市场 - 按地理位置

  • 介绍
    • 按地理位置分類的细分市场占有率分析
  • 北美洲
    • 概述
    • 北美朊病毒疾病治疗主要製造商
    • 北美市场规模和预测（按国家）
    • 北美市场规模和预测（按类型）
    • 北美市场规模与预测（以不同处理方式）
    • 北美市场规模和预测（按最终用户）
    • 我们
    • 加拿大
  • 欧洲
    • 概述
    • 欧洲朊病毒疾病治疗主要製造商
    • 欧洲市场规模和预测（按国家）
    • 欧洲市场规模与预测（按类型）
    • 欧洲市场规模与预测（按处理方式）
    • 欧洲市场规模和预测（按最终用户）
    • 德国
    • 义大利
    • 英国
    • 法国
    • 俄罗斯
    • 荷兰
    • 瑞典
    • 波兰
    • 欧洲其他地区
  • 亚太地区 (APAC)
    • 概述
    • 亚太地区朊病毒疾病治疗主要製造商
    • 亚太地区市场规模与预测（按国家）
    • 亚太地区市场规模与预测（按类型）
    • 亚太地区市场规模与预测（以不同处理方式）
    • 亚太地区市场规模和预测（按最终用户）
    • 印度
    • 中国
    • 日本
    • 韩国
    • 澳洲
    • 泰国
    • 印尼
    • 菲律宾
    • 亚太地区其他地区
  • 拉丁美洲
    • 概述
    • 拉丁美洲朊病毒疾病治疗主要製造商
    • 拉丁美洲市场规模与预测（按国家）
    • 拉丁美洲市场规模与预测（按类型）
    • 拉丁美洲市场规模与预测（以不同处理方式）
    • 拉丁美洲市场规模和预测（按最终用户）
    • 巴西
    • 墨西哥
    • 阿根廷
    • 哥伦比亚
    • 拉丁美洲其他地区
  • 中东和非洲
    • 概述
    • 中东和非洲朊病毒疾病治疗主要製造商
    • 中东和非洲市场规模及预测（按国家）
    • 中东和非洲市场规模及预测（按类型）
    • 中东及非洲市场规模及预测（依不同处理方式）
    • 中东和非洲市场规模和预测（按最终用户）
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 以色列
    • 土耳其
    • 阿尔及利亚
    • 埃及
    • MEA 的其余部分

第 11 章：主要供应商分析 - 朊病毒疾病治疗产业

  • 竞争仪表板
  • 公司简介
    • CureVac AG
    • Prionics AG
    • Neurotech Pharmaceuticals
    • Prothena Biosciences
    • Alnylam Pharmaceuticals
    • IONIS Pharmaceuticals
    • Biogen
    • Eli Lilly and Company
    • Amgen Inc.
    • Genentech
    • Wave Life Sciences
    • Orphazyme A/S
    • Sage Therapeutics
    • Alector Inc.
    • Tetra Discovery Partners

第 12 章：360 度分析师视角

第 13 章：附录

  • 研究方法
  • 参考
  • 缩写
  • 免责声明
  • 联络我们
简介目录
Product Code: ANV4039

REPORT HIGHLIGHT

Prion Disease Treatment Market size was valued at USD 4,984.98 million in 2023, expanding at a CAGR of 4.99% from 2024 to 2032.

Prion diseases are a group of progressive neurodegenerative disorders caused by abnormal, misfolded proteins known as prions. These prions induce other proteins in the brain to also misfold, leading to brain damage and severe neurological symptoms. The most well-known prion diseases include Creutzfeldt-Jakob disease, Bovine Spongiform Encephalopathy (mad cow disease), and Kuru. Symptoms often involve rapid cognitive decline, motor dysfunction, and behavioral changes. Currently, there is no cure for prion diseases, and treatment mainly focuses on alleviating symptoms and providing supportive care. Research is ongoing to find effective therapies, but the unique nature of prions and their ability to resist conventional treatments pose significant challenges. Early diagnosis and management can help in improving the quality of life for affected individuals.

Prion Disease Treatment Market- Market Dynamics

Rising interest in personalized medicine for specific prion strains drives niche market growth.

The growing interest in personalized medicine for specific prion strains is a key driver of market expansion. This approach tailors' diagnostics and treatments to the unique characteristics of different population strains, enhancing the effectiveness of interventions. Recent data from the National Institute of Neurological Disorders and Stroke (NINDS) showed that personalized medicine strategies could improve diagnostic accuracy for prion diseases by up to 30%. These advancements highlight the potential for more precise and effective treatment options, directly influencing market dynamics.

As the healthcare sector increasingly embraces individualized approaches, there is a rising demand for specialized diagnostic tools and customized therapies. This demand fosters innovation and growth in the niche market for Parkinson's disease management, emphasizing the transformative potential of personalized medicine in addressing complex neurodegenerative conditions.

Prion Disease Treatment Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 4.99% over the forecast period (2024-2032)

Based on Type segmentation, Creutzfeldt-Jakob Disease (CJD) was predicted to show maximum market share in the year 2023

Based on Treatment segmentation, antidepressant medications was the leading type in 2023

On the basis of region, North America was the leading revenue generator in 2023

Prion Disease Treatment Market- Segmentation Analysis:

The Global Prion Disease Treatment Market is segmented on the basis of Type, Treatment, End User, and Region.

The market is divided into four categories based on Type: Creutzfeldt-Jakob Disease (CJD), Variant Creutzfeldt-Jakob Disease (CJD), Variably Protease-Sensitive Prionopathy, Gerstmann-Straussler-Scheinker Disease, Others. In the prion disease treatment market, Creutzfeldt-Jakob Disease (CJD) is the most prominent and significant segment. CJD is the most common prion disease in humans, and it is a major focus due to its prevalence compared to other prion disorders. Creutzfeldt-Jakob Disease comes in several forms, including sporadic, genetic, and acquired. The sporadic form is the most common and occurs without any known cause. The treatment landscape for CJD is particularly active due to the high level of research interest and the severe nature of the disease. Efforts to develop effective treatments or therapies for CJD often drive the market, making it the dominant segment.

The market is divided into two categories based on Treatment: Antidepressants, Antipsychotic agents, and Others. In the prion disease treatment market, antidepressant medications are more prominent and significant compared to antipsychotic agents. Antidepressants are often used in the management of prion diseases, particularly for alleviating symptoms such as depression, anxiety, and agitation, which are common in patients with prion disorders like Creutzfeldt-Jakob Disease (CJD). Although there is no cure for prion disease, antidepressants can help improve the quality of life by managing secondary symptoms. The focus on antidepressants in research and treatment strategies for prion diseases makes this segment more significant and dominant in the market.

Prion Disease Treatment Market- Geographical Insights

In North America, prion disease treatment is an area of ongoing research with limited clinical options. Prion diseases, such as Creutzfeldt-Jakob Disease (CJD), are rare and characterized by progressive neurodegeneration. Treatment strategies focus on symptomatic management and experimental therapies. There is a significant emphasis on research to develop effective drugs, with several clinical trials exploring novel compounds and approaches, such as gene therapy and immunotherapy.

The North American regulatory environment supports these efforts through funding and regulatory pathways, though the complexity of prion diseases presents challenges. Collaboration among research institutions, healthcare providers, and pharmaceutical companies is crucial for advancing treatment options and improving patient outcomes.

Prion Disease Treatment Market- Competitive Landscape:

The competitive landscape for prion disease treatment includes a variety of biotech and pharmaceutical companies tackling the unique challenges of these disorders. CureVac AG is exploring mRNA technologies for potential treatments, while Prionics AG specializes in prion disease diagnostics. Neurotech Pharmaceuticals and Prothena Biosciences are developing therapies for neurodegenerative conditions that could be relevant to prion diseases. Alnylam Pharmaceuticals and IONIS Pharmaceuticals work on RNA-based therapies that may impact prion disease treatment. Major players such as Biogen, Eli Lilly and Company, and Amgen Inc. invest in broader neurodegenerative research with potential Treatments to prion diseases. Genentech (Roche Group) focuses on innovative neurological therapies. Wave Life Sciences and Orphazyme A/S are exploring RNA-targeted and rare disease therapies, respectively. Sage Therapeutics works on neurodegenerative disorders, while Alector Inc. develops immunotherapies. Tetra Discovery Partners is also researching treatments for neurological conditions that might intersect with prion diseases. This diverse group of companies highlights the ongoing efforts and innovations aimed at addressing the complex nature of prion diseases.

Recent Developments:

In June 2024, The CHARMED collaboration unveiled a promising treatment candidate for prion diseases, potentially offering new hope for these currently untreatable and fatal conditions.

In August 2023, Elite Pharmaceuticals Inc. declared that EP-1 had been given the Fast Track designation by the FDA to treat CJD. The procedure known as "Fast Track designation" intended to speed up and simplify the development of medications aimed at treating serious or life-threatening illnesses.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL PRION DISEASE TREATMENT MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

  • CureVac AG
  • Prionics AG
  • Neurotech Pharmaceuticals
  • Prothena Biosciences
  • Alnylam Pharmaceuticals
  • IONIS Pharmaceuticals
  • Biogen
  • Eli Lilly and Company
  • Amgen Inc.
  • Genentech
  • Wave Life Sciences
  • Orphazyme A/S
  • Sage Therapeutics
  • Alector Inc.
  • Tetra Discovery Partners

GLOBAL PRION DISEASE TREATMENT MARKET, BY TYPE- MARKET ANALYSIS, 2019 - 2032

  • Creutzfeldt-Jakob Disease (CJD)
  • Variant Creutzfeldt-Jakob Disease (CJD)
  • Variably Protease-Sensitive Prionopathy
  • Gerstmann-Straussler-Scheinker Disease
  • Others

GLOBAL PRION DISEASE TREATMENT MARKET, BY TREATMENT- MARKET ANALYSIS, 2019 - 2032

  • Antidepressant
  • Antipsychotic Agents
  • Others

GLOBAL PRION DISEASE TREATMENT MARKET, BY END USER- MARKET ANALYSIS, 2019 - 2032

  • Hospitals
  • Homecare settings
  • Others

GLOBAL PRION DISEASE TREATMENT MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

  • North America
  • The U.S.
  • Canada
  • Europe
  • Germany
  • France
  • Italy
  • Spain
  • United Kingdom
  • Russia
  • Netherlands
  • Sweden
  • Poland
  • Rest of Europe
  • Asia Pacific
  • India
  • China
  • South Korea
  • Japan
  • Australia
  • Thailand
  • Indonesia
  • Philippines
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • United Arab Emirates
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Rest of MEA

Table of Contents

1. Prion Disease Treatment Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Prion Disease Treatment Market Snippet by Type
    • 2.1.2. Prion Disease Treatment Market Snippet by Treatment
    • 2.1.3. Prion Disease Treatment Market Snippet by End User
    • 2.1.4. Prion Disease Treatment Market Snippet by Country
    • 2.1.5. Prion Disease Treatment Market Snippet by Region
  • 2.2. Competitive Insights

3. Prion Disease Treatment Key Market Trends

  • 3.1. Prion Disease Treatment Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Prion Disease Treatment Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Prion Disease Treatment Market Opportunities
  • 3.4. Prion Disease Treatment Market Future Trends

4. Prion Disease Treatment Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Prion Disease Treatment Market: COVID-19 Impact Analysis

  • 5.1. Pre-COVID-19 Impact Analysis
  • 5.2. Post-COVID-19 Impact Analysis
    • 5.2.1. Top Performing Segments
    • 5.2.2. Marginal Growth Segments
    • 5.2.3. Top Looser Segments
    • 5.2.4. Marginal Loss Segments

6. Prion Disease Treatment Market Landscape

  • 6.1. Prion Disease Treatment Market Share Analysis, 2023
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Prion Disease Treatment Market - By Type

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Type, 2023 & 2032 (%)
    • 7.1.2. Creutzfeldt-Jakob Disease (CJD)
    • 7.1.3. Variant Creutzfeldt-Jakob Disease (CJD)
    • 7.1.4. Variably Protease-Sensitive Prionopathy
    • 7.1.5. Gerstmann-Straussler-Scheinker Disease
    • 7.1.6. Others

8. Prion Disease Treatment Market - By Treatment

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Treatment, 2023 & 2032 (%)
    • 8.1.2. Antidepressant
    • 8.1.3. Antipsychotic Agents
    • 8.1.4. Others

9. Prion Disease Treatment Market - By End User

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By End User, 2023 & 2032 (%)
    • 9.1.2. Hospitals
    • 9.1.3. Homecare settings
    • 9.1.4. Others

10. Prion Disease Treatment Market- By Geography

  • 10.1. Introduction
    • 10.1.1. Segment Share Analysis, By Geography, 2023 & 2032 (%)
  • 10.2. North America
    • 10.2.1. Overview
    • 10.2.2. Prion Disease Treatment Key Manufacturers in North America
    • 10.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.2.4. North America Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 10.2.5. North America Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
    • 10.2.6. North America Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 10.2.7. U.S.
      • 10.2.7.1. Overview
      • 10.2.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.2.7.3. U.S. Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.2.7.4. U.S. Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 10.2.7.5. U.S. Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 10.2.8. Canada
      • 10.2.8.1. Overview
      • 10.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.2.8.3. Canada Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.2.8.4. Canada Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 10.2.8.5. Canada Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  • 10.3. Europe
    • 10.3.1. Overview
    • 10.3.2. Prion Disease Treatment Key Manufacturers in Europe
    • 10.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.3.4. Europe Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 10.3.5. Europe Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
    • 10.3.6. Europe Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 10.3.7. Germany
      • 10.3.7.1. Overview
      • 10.3.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.7.3. Germany Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.3.7.4. Germany Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 10.3.7.5. Germany Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 10.3.8. Italy
      • 10.3.8.1. Overview
      • 10.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.8.3. Italy Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.3.8.4. Italy Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 10.3.8.5. Italy Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 10.3.9. United Kingdom
      • 10.3.9.1. Overview
      • 10.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.9.3. United Kingdom Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.3.9.4. United Kingdom Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 10.3.9.5. United Kingdom Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 10.3.10. France
      • 10.3.10.1. Overview
      • 10.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.10.3. France Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.3.10.4. France Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 10.3.10.5. France Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 10.3.11. Russia
      • 10.3.11.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.11.2. Russia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.3.11.3. Russia Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 10.3.11.4. Russia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 10.3.12. Netherlands
      • 10.3.12.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.12.2. Netherlands Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.3.12.3. Netherlands Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 10.3.12.4. Netherlands Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 10.3.13. Sweden
      • 10.3.13.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.13.2. Sweden Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.3.13.3. Sweden Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 10.3.13.4. Sweden Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 10.3.14. Poland
      • 10.3.14.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.14.2. Poland Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.3.14.3. Poland Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 10.3.14.4. Poland Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 10.3.15. Rest of Europe
      • 10.3.15.1. Overview
      • 10.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.15.3. Rest of the Europe Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.3.15.4. Rest of the Europe Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 10.3.15.5. Rest of the Europe Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  • 10.4. Asia Pacific (APAC)
    • 10.4.1. Overview
    • 10.4.2. Prion Disease Treatment Key Manufacturers in Asia Pacific
    • 10.4.3. Asia Pacific Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.4.4. Asia Pacific Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 10.4.5. Asia Pacific Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
    • 10.4.6. Asia Pacific Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 10.4.7. India
      • 10.4.7.1. Overview
      • 10.4.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.7.3. India Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.4.7.4. India Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 10.4.7.5. India Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 10.4.8. China
      • 10.4.8.1. Overview
      • 10.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.8.3. China Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.4.8.4. China Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 10.4.8.5. China Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 10.4.9. Japan
      • 10.4.9.1. Overview
      • 10.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.9.3. Japan Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.4.9.4. Japan Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 10.4.9.5. Japan Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 10.4.10. South Korea
      • 10.4.10.1. Overview
      • 10.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.10.3. South Korea Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.4.10.4. South Korea Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 10.4.10.5. South Korea Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 10.4.11. Australia
      • 10.4.11.1. Overview
      • 10.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.11.3. Australia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.4.11.4. Australia Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 10.4.11.5. Australia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 10.4.12. Thailand
      • 10.4.12.1. Overview
      • 10.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.12.3. Thailand Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.4.12.4. Thailand Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 10.4.12.5. Thailand Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 10.4.13. Indonesia
      • 10.4.13.1. Overview
      • 10.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.13.3. Indonesia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.4.13.4. Indonesia Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 10.4.13.5. Indonesia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 10.4.14. Philippines
      • 10.4.14.1. Overview
      • 10.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.14.3. Philippines Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.4.14.4. Philippines Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 10.4.14.5. Philippines Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 10.4.15. Rest of APAC
      • 10.4.15.1. Overview
      • 10.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.15.3. Rest of APAC Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.4.15.4. Rest of APAC Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 10.4.15.5. Rest of APAC Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  • 10.5. Latin America
    • 10.5.1. Overview
    • 10.5.2. Prion Disease Treatment Key Manufacturers in Latin America
    • 10.5.3. Latin America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.5.4. Latin America Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 10.5.5. Latin America Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
    • 10.5.6. Latin America Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 10.5.7. Brazil
      • 10.5.7.1. Overview
      • 10.5.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.7.3. Brazil Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.5.7.4. Brazil Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 10.5.7.5. Brazil Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 10.5.8. Mexico
      • 10.5.8.1. Overview
      • 10.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.8.3. Mexico Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.5.8.4. Mexico Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 10.5.8.5. Mexico Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 10.5.9. Argentina
      • 10.5.9.1. Overview
      • 10.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.9.3. Argentina Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.5.9.4. Argentina Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 10.5.9.5. Argentina Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 10.5.10. Colombia
      • 10.5.10.1. Overview
      • 10.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.10.3. Colombia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.5.10.4. Colombia Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 10.5.10.5. Colombia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 10.5.11. Rest of LATAM
      • 10.5.11.1. Overview
      • 10.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.11.3. Rest of LATAM Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.5.11.4. Rest of LATAM Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 10.5.11.5. Rest of LATAM Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  • 10.6. Middle East and Africa
    • 10.6.1. Overview
    • 10.6.2. Prion Disease Treatment Key Manufacturers in Middle East and Africa
    • 10.6.3. Middle East and Africa Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.6.4. Middle East and Africa Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 10.6.5. Middle East and Africa Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
    • 10.6.6. Middle East and Africa Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 10.6.7. Saudi Arabia
      • 10.6.7.1. Overview
      • 10.6.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.7.3. Saudi Arabia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.6.7.4. Saudi Arabia Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 10.6.7.5. Saudi Arabia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 10.6.8. United Arab Emirates
      • 10.6.8.1. Overview
      • 10.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.8.3. United Arab Emirates Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.6.8.4. United Arab Emirates Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 10.6.8.5. United Arab Emirates Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 10.6.9. Israel
      • 10.6.9.1. Overview
      • 10.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.9.3. Israel Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.6.9.4. Israel Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 10.6.9.5. Israel Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 10.6.10. Turkey
      • 10.6.10.1. Overview
      • 10.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.10.3. Turkey Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.6.10.4. Turkey Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 10.6.10.5. Turkey Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 10.6.11. Algeria
      • 10.6.11.1. Overview
      • 10.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.11.3. Algeria Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.6.11.4. Algeria Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 10.6.11.5. Algeria Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 10.6.12. Egypt
      • 10.6.12.1. Overview
      • 10.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.12.3. Egypt Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.6.12.4. Egypt Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 10.6.12.5. Egypt Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 10.6.13. Rest of MEA
      • 10.6.13.1. Overview
      • 10.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.13.3. Rest of MEA Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.6.13.4. Rest of MEA Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 10.6.13.5. Rest of MEA Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)

11. Key Vendor Analysis- Prion Disease Treatment Industry

  • 11.1. Competitive Dashboard
  • 11.2. Company Profiles
    • 11.2.1. CureVac AG
    • 11.2.2. Prionics AG
    • 11.2.3. Neurotech Pharmaceuticals
    • 11.2.4. Prothena Biosciences
    • 11.2.5. Alnylam Pharmaceuticals
    • 11.2.6. IONIS Pharmaceuticals
    • 11.2.7. Biogen
    • 11.2.8. Eli Lilly and Company
    • 11.2.9. Amgen Inc.
    • 11.2.10. Genentech
    • 11.2.11. Wave Life Sciences
    • 11.2.12. Orphazyme A/S
    • 11.2.13. Sage Therapeutics
    • 11.2.14. Alector Inc.
    • 11.2.15. Tetra Discovery Partners

12. 360 Degree Analyst View

13. Appendix

  • 13.1. Research Methodology
  • 13.2. References
  • 13.3. Abbreviations
  • 13.4. Disclaimer
  • 13.5. Contact Us